Sign inJoin waitlistJoin the waitlist

Catherine Shu

Director of Thoracic Medical Oncology Service · CUMC

Credentials: · · · ·

History

CUMC
Present

Memorial Sloan-Kettering Cancer Center
NewYork-Presbyterian Hospital/Columbia University Medical Center
NewYork-Presbyterian Hospital/Columbia University Medical Center
Columbia University College of Physicians and Surgeons
2009
Memorial Sloan-Kettering Cancer Center
Princeton University

Research

Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
Journal of Clinical Oncology · 2021 · 551 citations
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
The Lancet Oncology · 2020 · First of 16 authors · 540 citations
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers
Annals of Oncology · 2018 · 288 citations

Anjali Saqi
23 papers
NR
Naiyer Rizvi
13 papers
Brian Henick
8 papers
Joshua Sonett
8 papers
LC
Lanyi Chen
8 papers · 8 as a fellow
Benjamin Herzberg
7 papers
John Heymach
7 papers
Mark Stoopler
6 papers
Rachel Sanborn
6 papers
Simon Cheng
6 papers
Tina Cascone
6 papers
Tony Wang
6 papers

Clinical trials

Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment
Principal investigator · Withdrawn · Phase 2
Catherine Shu
2022–2023
SGI-110 Plus Durvalumab/Tremelimumab in SCLC
Principal investigator · Completed · Phase 1
Catherine Shu
2017–2018
Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC
Principal investigator · Completed · Phase 2
Columbia University
2016–2022
Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers
Site PI · Unknown
Lung Cancer Mutation Consortium
2022–2026